Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 64.02M P/E - EPS this Y -8.20% Ern Qtrly Grth -
Income -29.85M Forward P/E -3.09 EPS next Y 8.50% 50D Avg Chg -9.00%
Sales 9.37M PEG - EPS past 5Y - 200D Avg Chg -41.00%
Dividend N/A Price/Book 8.78 EPS next 5Y - 52W High Chg -75.00%
Recommedations 2.00 Quick Ratio 2.06 Shares Outstanding 4.45M 52W Low Chg 105.00%
Insider Own 5.29% ROA -35.67% Shares Float 2.61M Beta 6.94
Inst Own 60.76% ROE -265.00% Shares Shorted/Prior 60.13K/74.29K Price 13.07
Gross Margin -108.07% Profit Margin - Avg. Volume 3,086,034 Target Price 59.50
Oper. Margin -274.10% Earnings Date Nov 10 Volume 7,569,807 Change 9.37%
Aptevo Therapeutics Inc. News
11/23/21 Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia
11/23/21 Aptevo Therapeutics Stock More Than Doubles After Leukemia Study News
11/15/21 Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting
11/12/21 Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights
11/11/21 Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021
11/11/21 Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting
11/02/21 BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors
07:05 AM Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021
10/26/21 Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436
09/28/21 Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging
08/17/21 Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
08/12/21 Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
07/16/21 Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference
06/29/21 Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
08:00 AM Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia
05/26/21 Aptevo Stock Gains on Encouraging Single-Agent Activity for APVO436 In Leukemia Patients
05/26/21 Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia
05/17/21 American Eagle Completes Magnetotelluric Survey at its Golden Trend Property in the Cortez, Nevada; Publishes Interview with CEO Anthony Moreau and VP of Exploration Mark Bradley
05/11/21 Aptevo Therapeutics Reports First Quarter 2021 Financial Results

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1/1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It is also developing APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer; and other pre-clinical development stage therapeutics focused on hematologic and solid tumors. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

APVO Chatroom

User Image ToniesPick Posted - 4 minutes ago

$APVO 18-23 fair value anything below ridiculous.

User Image ChartMill Posted - 27 minutes ago

$APVO was analyzed by 8 analysts. The buy consensus is at 83%. So analysts seem to be very confident about $APVO. https://www.chartmill.com/stock/analyzer/stock/APVO?view=analyst-ratings&utm_source=stocktwits&utm_medium=ANALYST&utm_content=APVO&utm_campaign=social_tracking

User Image runningwild Posted - 39 minutes ago

$APVO Monday madness will be here over 20

User Image romanlaz Posted - 1 hour ago

$APVO forming w, support is good, we will pop.

User Image Sammyflash Posted - 1 hour ago

$APVO end of year 50 $

User Image bankingoffthefear1 Posted - 1 hour ago

$APVO Monday we're fucked or golden

User Image ecoethcon Posted - 2 hours ago

$APVO As I stated in my earlier message about the trend here, longs should be in increasing control given the small float and the number of shares locked up by insiders, institutions, and now both committed longs and those trying to break even/make a big profit from buys at higher levels. Fintel now lists the borrow fee to be up to over 41% (it varies depending on your source or broker). The writing is on the wall for short sellers given this development and that the price has stabilized and has been slowly rising in the last few trading days. https://fintel.io/ss/us/apvo 8h 2021-11-27 04:55:44.166 41.04

User Image Helvetika Posted - 2 hours ago

$APVO Tang sold - its a bullish sign! Price will go up! this was 15$ before the news !!!!

User Image Harunkaraca Posted - 3 hours ago

$APVO

User Image allcharts Posted - 3 hours ago

$APVO APVO 2021-11-26 Technical Analysis Video: https://www.youtube.com/watch?v=yIlfuKqy-aI

User Image romanlaz Posted - 5 hours ago

$APVO monday we win

User Image romanlaz Posted - 6 hours ago

$APVO 31% short interest, double w created. Monday will be hot

User Image VertiCall Posted - 6 hours ago

$APVO made two inside bars in the daily chart. A break over 14.10 and then 15.33 could give it some new power. On watchlist for monday. ⭐️⤴️🍀 🚀 Made +171% since first alert Tuesday! Chart-Setup in Comments ⤵️

User Image Kaiz1986 Posted - 7 hours ago

$APVO very strong outlook next week

User Image tradersgraphics Posted - 7 hours ago

$APVO APVO 2021-11-26 Daily Forecast Video: https://www.youtube.com/watch?v=kUWYoG50sdg

User Image Qkuincy Posted - 8 hours ago

$APVO

User Image romanlaz Posted - 8 hours ago

$APVO a must buy on monday

User Image romanlaz Posted - 8 hours ago

$APVO 🚀🚀

User Image ChartMill Posted - 10 hours ago

$APVO: The EPS has grown by an impressive 28.45% over the past year. https://www.chartmill.com/stock/quote/APVO/fundamental-analysis?key=46198d81-8ab5-463f-a652-518c657793fc&utm_source=stocktwits&utm_medium=FA&utm_content=APVO&utm_campaign=social_tracking

User Image I_Wanna_Be_Rich1992 Posted - 10 hours ago

$APVO I’m aware that some people already heard and seen the news from Tang but let’s see that glorious picture to celebrate the big L on their part! Rejected B/O for $50 p/s and has been selling their shares at a loss due to personal beef. Apologies for stirring the pot, but y’all know that it’s true 🤷‍♂️ Analysts and retailer investors PT range from $30 - $80, this play saves lives and for us, money will change ours. Good luck to all!

User Image I_Wanna_Be_Rich1992 Posted - 11 hours ago

$APVO If the board of directors rejected the buy out offer of $50 from Tang, you’d expect they value their price per share to be over $50 right? 👀 let’s see what happens in the next 1-4 months.

User Image Westcoastcrippler Posted - 11 hours ago

$APVO Kevin Tang?

User Image jvuskeee Posted - 13 hours ago

$APVO PT for next week?

User Image MisterDollar Posted - 13 hours ago

$APVO Check out this massive W forming. Let's go!

User Image Well2Do Posted - 13 hours ago

THESE SHOULD BE ON YOUR BUY LIST. THE COMING WEEKS/MONTHS SHOULD BE VERY REWARDING! NOW YOU KNOW! $APVO $SFOR $SONN

User Image CBBB Posted - 13 hours ago

$APVO How is this Company In line with Kura ?

User Image fibeak Posted - 14 hours ago

$APVO

User Image Nakedbutnotshort Posted - 14 hours ago

$APVO TANG! What a

User Image allcharts Posted - 14 hours ago

$APVO APVO 2021-11-26 Dark Pool & Short Interest Data: https://www.youtube.com/watch?v=YzaS5PfxzXc

User Image Jadedtrader Posted - 14 hours ago

$APVO I like the current set up. But it's too bad that options aren't available for this stock: Damn!

Analyst Ratings
Roth Capital Buy May 27, 21
Piper Sandler Overweight Nov 10, 20
Roth Capital Buy Apr 10, 18
PiperJaffray Overweight Sep 8, 16
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
- - - Nov 06 Buy 17.82 1,436,675 25,601,548 1,760,000 11/06/20